research Les Visiteurs des malades
5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
Search
for
Sort by
Research
720-750 / 1000+ results
research Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis
A woman developed severe kidney injury from using simvastatin with ciclosporin, highlighting the need for careful monitoring when combining these drugs.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Subcutaneous injection of genetically engineered exosomes for androgenic alopecia treatment
EX104 shows promise in treating hair loss by promoting hair growth and improving scalp health.
research Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
research 341 ANDROGENETIC ALOPECIA AT VARIOUS AGES AND PROSTATE CANCER RISK IN AN EQUAL ACCESS MULTIETHNIC CASE CONTROL SERIES OF VETERANS
Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
research Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
Azathioprine caused side effects in over half of the Korean pediatric inflammatory bowel disease patients, requiring close monitoring.
research Galenic-Pharmaceutical Study of Pieces of Proscar (Finasteride 5mg) and Finasteride 1mg Capsules versus Propecia® in the Treatment of Androgenetic Alopecia
research Delayed Onset of Alopecia Areata in a Patient on Ocrelizumab for Multiple Sclerosis: A Case Report
Ocrelizumab may cause delayed hair loss in some patients.
research Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia
REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
research Skin health promoting effects of a proprietary nutraceutical ingredient (SesZen-BioTM): a placebo controlled, double-blind, and randomized clinical study
SesZen-BioTM improves skin health and reduces signs of aging.
research Chronic exposures to the herbicide atrazine and the pharmaceutical finasteride disrupt sex steroid and thyroid hormone signalling and gonadal development in frogs
Atrazine and finasteride disrupt hormone signaling and affect frog development.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
research PENANGANAN RAMBUT RONTOK JENIS ALOPECIA ANDROGENETIC DENGAN AKUPUNKTUR TITIK ZUSANLI (ST36), ZHUBIN (KI9), SHAOFU (HT8), DAN SANYINJIAO (SP6) SERTA GEL LIDAH BUAYA (Aloe vera) DAN DAUN SELEDRI (Apium graveolens L.)
Acupuncture and herbal treatments effectively reduced hair loss in androgenetic alopecia.
research Farmácia da Cruz, Porto e Serviços Farmacêuticos do Hospital General Universitario Gregorio Marañón, Espanha
research Prescribing Habits for Androgenic Alopecia among Dermatologists in Spain in 2019–2020: A Cross-Sectional Study
In Spain, dermatologists most commonly prescribe topical minoxidil and oral finasteride for male hair loss, and topical minoxidil and oral contraceptives for female hair loss. The use of oral dutasteride and oral minoxidil has significantly increased over the past three years.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
research Synthesis of a 4-azasteroid hormones compound
Finasteride was successfully synthesized from Pregnadienolone acetate.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Konvergentna validacija farmakoekonomskih aspekata terapije benigne hiperplazije prostate u Crnoj Gori
Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
research No increased risk of alopecia in ankylosing spondylitis patients: A population‐based cohort study in Taiwan
People with ankylosing spondylitis in Taiwan don't have a higher chance of getting alopecia.
research Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
Bromhexine and spironolactone together reduced COVID-19 symptoms and hospitalization time without side effects.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
RC48 shows promise for treating certain advanced cancers, but more research is needed.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.